View Older Stories View More Recent Stories

Sep 13, 2024 07:00AM Krystal Biotech to Present at 2024 Cantor Global Healthcare Conference
Sep 6, 2024 07:00AM Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference
Aug 28, 2024 07:01AM Krystal Biotech's (KRYS) Jeune Aesthetics Announces Phase 1 Positive Interim Safety and Efficacy Results for KB301
Aug 28, 2024 07:00AM Jeune Aesthetics Announces Phase 1 Positive Interim Safety and Efficacy Results for KB301 in the Treatment of Lateral Canthal Lines and Dynamic Wrinkles of the Décolleté
Aug 5, 2024 08:00AM Krystal Biotech Announces Second Quarter 2024 Financial Results and Provides Business Updates
Jul 26, 2024 08:00AM Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024
Jun 5, 2024 07:00AM Krystal Biotech to Present at Goldman Sachs 45th Annual Global Healthcare Conference
May 15, 2024 07:00AM Krystal Biotech to Present at the American Thoracic Society 2024 International Conference
May 8, 2024 07:00AM Krystal Biotech to Present at BofA Securities 2024 Health Care Conference
May 6, 2024 08:00AM Krystal Biotech Announces First Quarter 2024 Financial Results and Provides Business Updates
May 2, 2024 07:00AM Krystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting
Apr 26, 2024 07:00AM Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024
Apr 26, 2024 07:00AM Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024
Apr 22, 2024 07:00AM Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung
Apr 4, 2024 07:00AM Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting
Feb 28, 2024 07:00AM Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference
Feb 26, 2024 08:00AM Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
Feb 20, 2024 07:00AM Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
Feb 13, 2024 07:00AM Krystal Biotech (KRYS) Granted FDA Fast Track Designation for KB707
Feb 13, 2024 07:00AM Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung
Feb 8, 2024 07:03AM Krystal Biotech (KRYS) Reports Publication on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis Bullosa
Feb 8, 2024 07:00AM Krystal Biotech Announces Publication in the New England Journal of Medicine on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis Bullosa
Feb 1, 2024 07:00AM Krystal Biotech to Present at Guggenheim 6th Annual Biotechnology Conference
Jan 4, 2024 07:02AM Krystal Biotech (KRYS) Receives Permanent J-code (J3401) for VYJUVEK
Jan 4, 2024 07:00AM Krystal Biotech Receives Permanent J-code (J3401) for VYJUVEK®
Dec 19, 2023 07:00AM Krystal Biotech (KRYS) Receives Orphan Drug Designation from the Japanese MHLW for Beremagene Geperpavec-svdt
Dec 19, 2023 07:00AM Krystal Biotech Receives Orphan Drug Designation from the Japanese MHLW for Beremagene Geperpavec-svdt (B-VEC)
Nov 27, 2023 07:04AM Krystal Biotech (KRYS) Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa
Nov 27, 2023 07:00AM Krystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa
Nov 9, 2023 07:00AM Krystal Biotech to Present at the Stifel 2023 Healthcare Conference
Nov 6, 2023 07:00AM Krystal Biotech Announces Third Quarter 2023 Financial Results and Provides Business Update
Oct 30, 2023 07:00AM Krystal Biotech to Report Third Quarter 2023 Financial Results on November 6, 2023
Sep 28, 2023 07:00AM Krystal Biotech to Present at the Chardan 7th Annual Genetic Medicines Conference
Sep 21, 2023 09:00AM Krystal Biotech (KRYS) Granted FDA Clearance of IND Application for KB408
Sep 21, 2023 09:00AM Krystal Biotech Announces FDA Clearance of Investigational New Drug Application for KB408 for the Treatment of Type 1 Alpha-1 Antitrypsin Deficiency
Sep 7, 2023 07:00AM Krystal Biotech to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
Sep 5, 2023 07:03AM Krystal Biotech (KRYS) Granted FDA Orphan Drug Designation for KB408
Sep 5, 2023 07:00AM Krystal Biotech Announces Orphan Drug Designation Granted to KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency
Aug 21, 2023 07:01AM Krystal Biotech (KRYS) Announces Sale of Priority Review Voucher for $100 Million
Aug 21, 2023 07:00AM Krystal Biotech Announces Sale of Priority Review Voucher for $100 Million
Aug 7, 2023 07:00AM Krystal Biotech Announces Second Quarter 2023 Financial Results and Operational Highlights
Jul 26, 2023 04:15PM Krystal Biotech (KRYS) Announces Pipeline Expansion into Oncology and FDA Acceptance of IND Application for KB707
Jul 26, 2023 04:14PM Krystal Biotech Announces Pipeline Expansion into Oncology and FDA Acceptance of IND Application for Lead Oncology Candidate KB707
Jul 3, 2023 07:00AM Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of KB407 for the Treatment of Cystic Fibrosis
Jun 5, 2023 07:00AM Krystal Biotech to Present at Upcoming Investor Conferences
May 22, 2023 07:01AM Krystal Biotech (KRYS) sells 1.73 million shares at $92.50 in private placement
May 22, 2023 07:00AM Krystal Biotech Announces $160 Million Private Placement Equity Financing
May 19, 2023 02:03PM Krystal Biotech (KRYS) Receives FDA Approval for VYJUVEK
May 19, 2023 01:57PM Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK™ (beremagene geperpavec-svdt) for the Treatment of Dystrophic Epidermolysis Bullosa
May 8, 2023 08:23AM Krystal Biotech Announces First Quarter 2023 Financial Results and Operational Highlights
View More Recent Stories View Older Stories